
The Future of Psychedelic Medicine

Mission
Using evidence-informed research, we want to unlock human performance and empower people to achieve their full potential.
Psychedelic medicine is the frontier of mental health and wellness
Social attitudes and behaviours towards mental health are shifting away from pharmaceuticals in favour of sustainably resourced compounds derived from fungi and plant medicines.
350 Million
People globally are affected by a form of depression.
1 Trillion
Dollars lost annually in global workforce productivity due to depression and anxiety.
0
Formulas standardized across clinical studies of psychedelic compounds.
HAVN Life is part of a global community taking an active role in formulations and research for microdosing therapies which have shown effectiveness in addressing mental health and performance.
Press Releases
HAVN LIFE SCIENCES Inc. PROVIDES BI-WEEKLY MCTO STATUS UPDATE
September 27, 2023
Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of
Read More →
Press Releases
HAVN LIFE SCIENCES Inc. PROVIDES BI-WEEKLY MCTO STATUS UPDATE
September 15, 2023
Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of
Read More →
Press Releases
HAVN ANNOUNCES ANTICIPATED LATE FILING OF FINANCIAL STATEMENTS AND APPLICATION FOR MANAGEMENT CEASE TRADE ORDER
August 30, 2023
Vancouver, BC – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of
Read More →